Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIOOTCMKTS:CRLBFNASDAQ:EWTXNASDAQ:HRMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$33.65+2.9%$31.15$23.42▼$62.58$1.89B0.73650,533 shs274,744 shsCRLBFCresco Labs$0.51-0.1%$0.66$0.43▼$2.05$249.93M1.47746,510 shs342,020 shsEWTXEdgewise Therapeutics$13.06-8.9%$14.77$10.60▼$38.12$1.51B0.281.21 million shs3.42 million shsHRMYHarmony Biosciences$31.86+0.9%$32.78$26.47▼$41.61$1.81B0.87625,333 shs453,698 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.87%-5.21%+11.42%+11.13%-22.39%CRLBFCresco Labs+1.58%+5.90%-22.98%-34.82%-70.10%EWTXEdgewise Therapeutics-8.86%-9.74%-8.80%-43.88%-25.29%HRMYHarmony Biosciences+0.92%-1.91%-5.71%-4.01%+2.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.2064 of 5 stars3.41.00.04.23.20.81.9CRLBFCresco Labs0.676 of 5 stars0.03.00.00.02.00.01.3EWTXEdgewise Therapeutics2.7747 of 5 stars4.41.00.00.01.63.30.0HRMYHarmony Biosciences4.6801 of 5 stars4.61.00.00.02.23.34.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6074.15% UpsideCRLBFCresco Labs 3.00BuyN/AN/AEWTXEdgewise Therapeutics 2.78Moderate Buy$39.78204.58% UpsideHRMYHarmony Biosciences 3.13Buy$53.6368.31% UpsideCurrent Analyst Ratings BreakdownLatest CRLBF, AGIO, EWTX, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$48.006/3/2025CRLBFCresco LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy6/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M53.40N/AN/A$27.02 per share1.25CRLBFCresco Labs$724.34M0.34N/AN/A$0.79 per share0.64EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/AHRMYHarmony Biosciences$714.73M2.56$2.97 per share10.71$11.56 per share2.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.99N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)CRLBFCresco Labs-$74.44M-$0.24N/AN/AN/A-11.86%-21.77%-6.00%8/6/2025 (Estimated)EWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.95%-29.45%8/6/2025 (Estimated)HRMYHarmony Biosciences$145.49M$2.6212.1610.240.4720.53%24.32%15.92%8/5/2025 (Estimated)Latest CRLBF, AGIO, EWTX, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$164.37 million$165.76 million5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45-$0.43+$0.02-$0.43N/AN/A5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ACRLBFCresco LabsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93CRLBFCresco Labs1.632.751.98EWTXEdgewise TherapeuticsN/A20.9920.99HRMYHarmony Biosciences0.223.673.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ACRLBFCresco Labs0.05%EWTXEdgewise TherapeuticsN/AHRMYHarmony Biosciences86.23%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%CRLBFCresco LabsN/AEWTXEdgewise Therapeutics23.20%HRMYHarmony Biosciences23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableCRLBFCresco Labs2,900491.02 millionN/ANot OptionableEWTXEdgewise Therapeutics60105.20 million80.79 millionOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableCRLBF, AGIO, EWTX, and HRMY HeadlinesRecent News About These CompaniesFirst Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - NasdaqJune 24 at 12:35 AM | nasdaq.comNeedham Reiterates a Buy Rating on Harmony Biosciences (HRMY)June 24 at 7:35 PM | msn.comAnalysts Set Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Target Price at $53.63June 24 at 2:37 AM | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comExchange Traded Concepts LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 20, 2025 | marketbeat.comHarmony Biosciences obtains favorable settlement in litigation over generic WakixJune 19, 2025 | drugstorenews.comDSG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 18, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short InterestJune 17, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Trading Down 4.5% - Should You Sell?June 12, 2025 | marketbeat.com77,867 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CX InstitutionalJune 12, 2025 | marketbeat.comMillennium Management LLC Has $218,000 Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on HRMY FY2026 EarningsJune 11, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement SystemJune 10, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (HRMY): A Bull Case TheoryJune 9, 2025 | insidermonkey.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLCJune 9, 2025 | marketbeat.comHarmony Biosciences Holdings (HRMY) Shares Cross Below 200 DMAJune 7, 2025 | nasdaq.comHarmony Biosciences settles generic drug litigation, strengthens patentJune 6, 2025 | finance.yahoo.comHarmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA LitigationJune 5, 2025 | businesswire.comHennion & Walsh Asset Management Inc. Boosts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 5, 2025 | marketbeat.comHarmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | businesswire.comGAMMA Investing LLC Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRLBF, AGIO, EWTX, and HRMY Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$33.65 +0.94 (+2.87%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$34.92 +1.27 (+3.77%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Cresco Labs OTCMKTS:CRLBF$0.51 0.00 (-0.14%) As of 06/26/2025 03:57 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Edgewise Therapeutics NASDAQ:EWTX$13.06 -1.27 (-8.86%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$13.39 +0.33 (+2.56%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Harmony Biosciences NASDAQ:HRMY$31.86 +0.29 (+0.92%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$32.62 +0.76 (+2.40%) As of 06/26/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
